Abstract
Dofetilide is a new antiarrhythmic agent recently approved for the conversion of and maintenance of sinus rhythm in patients with atrial fibrillation (AF) and atrial flutter (AFI). Dofetilide is a selective class III antiarrhythmic drug which works by selectively blocking the rapid component of the delayed rectifier outward potassium current (Ikr). Dofetilide has been shown to prolong the effective refractory period which is accompanied by a dose-dependent prolongation of the QT and QTc intervals, with parallel increases in ventricular refractoriness. Approximately 80% of dofetilide is excreted in the urine which requires dose adjustments in renal insufficiency. The elimination half-life is approximately 10 h in patients with normal renal function. The therapeutic blood level range of dofetilide is presently unknown and monitoring of dofetilide blood levels is not available at this time. Clinical trials have shown dofetilide to be superior to flecainide in converting AFI patients to normal sinus rhythm (NSR) (70% vs. 9%; p
| Original language | English |
|---|---|
| Pages (from-to) | 759-771 |
| Number of pages | 13 |
| Journal | Drugs of Today |
| Volume | 36 |
| Issue number | 11 |
| DOIs | |
| State | Published - 2000 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Molecular Medicine
- Pharmacology (medical)
- Pharmacology
Cite this
Dofetilide : A new antiarrhythmic agent approved for conversion and/or maintenance of atrial fibrillation/atrial flutter. / Lenz, Thomas L.; Hilleman, Daniel E.
In: Drugs of Today, Vol. 36, No. 11, 2000, p. 759-771.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Dofetilide
T2 - A new antiarrhythmic agent approved for conversion and/or maintenance of atrial fibrillation/atrial flutter
AU - Lenz, Thomas L.
AU - Hilleman, Daniel E.
PY - 2000
Y1 - 2000
N2 - Dofetilide is a new antiarrhythmic agent recently approved for the conversion of and maintenance of sinus rhythm in patients with atrial fibrillation (AF) and atrial flutter (AFI). Dofetilide is a selective class III antiarrhythmic drug which works by selectively blocking the rapid component of the delayed rectifier outward potassium current (Ikr). Dofetilide has been shown to prolong the effective refractory period which is accompanied by a dose-dependent prolongation of the QT and QTc intervals, with parallel increases in ventricular refractoriness. Approximately 80% of dofetilide is excreted in the urine which requires dose adjustments in renal insufficiency. The elimination half-life is approximately 10 h in patients with normal renal function. The therapeutic blood level range of dofetilide is presently unknown and monitoring of dofetilide blood levels is not available at this time. Clinical trials have shown dofetilide to be superior to flecainide in converting AFI patients to normal sinus rhythm (NSR) (70% vs. 9%; p
AB - Dofetilide is a new antiarrhythmic agent recently approved for the conversion of and maintenance of sinus rhythm in patients with atrial fibrillation (AF) and atrial flutter (AFI). Dofetilide is a selective class III antiarrhythmic drug which works by selectively blocking the rapid component of the delayed rectifier outward potassium current (Ikr). Dofetilide has been shown to prolong the effective refractory period which is accompanied by a dose-dependent prolongation of the QT and QTc intervals, with parallel increases in ventricular refractoriness. Approximately 80% of dofetilide is excreted in the urine which requires dose adjustments in renal insufficiency. The elimination half-life is approximately 10 h in patients with normal renal function. The therapeutic blood level range of dofetilide is presently unknown and monitoring of dofetilide blood levels is not available at this time. Clinical trials have shown dofetilide to be superior to flecainide in converting AFI patients to normal sinus rhythm (NSR) (70% vs. 9%; p
UR - http://www.scopus.com/inward/record.url?scp=0034533650&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034533650&partnerID=8YFLogxK
U2 - 10.1358/dot.2000.36.11.601530
DO - 10.1358/dot.2000.36.11.601530
M3 - Review article
C2 - 12845335
AN - SCOPUS:0034533650
VL - 36
SP - 759
EP - 771
JO - Drugs of Today
JF - Drugs of Today
SN - 0025-7656
IS - 11
ER -